drugset / Trial / NCT03771586
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
RandomizedCrossoverQuadruple-blindBasic science
Summary
This study is a phase 1, double-blind, placebo-controlled crossover study of single, oral dose of SAGE-718 using a ketamine challenge, to evaluate the electrophysiology, safety, tolerability, and pharmacokinetics in healthy subjects
Timeline
- Start
- 2018-09-24
- Primary completion
- 2018-12-17
- Completion
- 2019-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalzanemdor | Small molecule | — | Oral |
| Background | Ketamine | Small molecule | — | — |
Indications
No indication recorded.